Meropenem

Drug Profile

Meropenem

Alternative Names: ICI 194660; ICI 213689; Mepem; Meronem; Meropen; Merozen; Merrem; Optinem; SM-7338; Zeropenem®

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer AstraZeneca; Sanofi; Sumitomo Dainippon Pharma
  • Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Community-acquired pneumonia; Febrile neutropenia; Skin and soft tissue infections

Most Recent Events

  • 24 Aug 2016 AstraZeneca plans to sell the commercialisation and development rights to late-stage small molecule antibiotics to Pfizer
  • 15 Mar 2016 Biomarkers information updated
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top